A post-hoc analysis of the phase 3b JUMP trial assessed outcomes in patients with myelofibrosis and baseline anemia who were treated with ruxolitinib alongside anemia-supportive therapies, according ...

Pediatric bone marrow myelofibrosis (MF) is a rare and complex hematological disorder characterized by cytopenia, bone marrow fibrosis, and systemic symptoms such as bone pain and fever.

Myelofibrosis is a type of blood cancer that causes scarring (fibrosis) in your bone marrow, which affects how your body makes blood cells.

Pelabresib (CPI-0610) plus Jakafi (ruxolitinib) continued to reduce splenomegaly, anemia, symptoms and bone marrow fibrosis in patients with JAK inhibitor-naive myelofibrosis, recent study findings ...

Primary myelofibrosis (PMF) is a rare bone marrow disorder that affects the production of blood cells. It causes scarring, or fibrosis, in the bone marrow, which reduces the body’s ability to ...

Join Drs Tania Jain and Pankit Vachhani as they discuss the nuance involved in the risk stratification of myelofibrosis and the ... platelets, circulating blasts, but also bone marrow, fibrosis ...

Sequencing Therapy. In a study in Cancer among 524 patients who received ruxolitinib for myelofibrosis, about 40.8% discontinued treatment at 3 years. The reasons for discontinuation included lack ...

Myelofibrosis remains a rare disease, even though recent attention to the condition might suggest otherwise. Annual incidence rates for 2000 to 2012 ranged from 0.1 to 1.0 per 100,000. Prevalence ...

When the gene becomes mutated your bone marrow may not function correctly. This means scar tissue can build up in your bone marrow. About 10 in 100 people with primary myelofibrosis (around 10%) will ...

PNH can occur de novo or in the presence of underlying bone marrow disorders, such as aplastic anemia (AA), myelodysplastic syndrome, or primary myelofibrosis . Thrombosis is a significant concern, ...

Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, validating LOXL2 as ...